istaroxime
Phase 2- Indications
- Acute heart failure, Early cardiogenic shock
Company intelligence / Profile preview
China Gateway Pharmaceutical Development specializes in R&D, production, and sales of pharmaceutical chemicals and intermediates. It operates as a CDMO/CRO with significant laboratory and pilot-scale manufacturing capacity. The company was acquired by Porton Pharma Solutions Ltd. in March 2022 to expand Porton's small/medium-scale CDMO capabilities.[1][2][3] No direct clinical results are reported as it primarily provides services rather than developing its own therapeutics.
2 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on China Gateway Pharmaceutical Development Co., Ltd..